News & Events

Press Releases

In the News

Events

FDA Grants SiSaf’s siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation

READ MORE

SiSaf Appoints Dr. Richard Goodfellow to Board of Directors

READ MORE

SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer

READ MORE

SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation

READ MORE

SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

READ MORE

RNA Therapeutics Company SiSaf to Present at Upcoming Conferences

READ MORE

SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor

READ MORE

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease

READ MORE

SiSaf Ltd utilizes Intoolab’s Tzager AI Platform

READ MORE

SiSaf Ltd Announces US$13.2 Million Series B Financing

READ MORE

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium

READ MORE

SiSaf announces licencing agreement to develop gene therapy for rare bone disease

READ MORE

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research

READ MORE

SiSaf Establishes Strategic Partnership with Avellino Labs

READ MORE

Next

UK osteopetrosis drug granted FDA Orphan Drug status

May 15, 2023

VIEW ARTICLE

Partnership formed to develop miRNA to treat pancreatic cancer

March 2, 2023

VIEW ARTICLE

Delivering RNA Therapeutics through Silicon Stabilized Hybrid Lipid Nanoparticles

November 21, 2022

VIEW ARTICLE

Delivering a New “Post-COVID” Generation of RNA Therapeutics

October 14, 2022

VIEW ARTICLE

SiSaf to seek FDA Orphan Drug Designation for SIS-101-ADO

October 13, 2022

VIEW ARTICLE

SiSaf takes steps with FDA for RNA therapeutic to treat rare genetic skeletal disorders

October 12, 2022

VIEW ARTICLE

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

September 12, 2022

VIEW ARTICLE

The challenges and trends of cell & gene therapies

September 6, 2022

VIEW ARTICLE

Sisaf to move siRNA program for bone growth disorder into the clinic

November 11, 2021

VIEW ARTICLE

SiSaf Exercises Option to License Gene Therapy for Rare Bone Disease

November 4, 2021

VIEW ARTICLE

Non-Viral Gene Therapies Get €51M Boost

October 4, 2021

VIEW ARTICLE

Croda International agrees new commercial arrangement with SiSaf

August 2, 2018

VIEW ARTICLE

Next

Bio€quity Europe 2023

Dublin

May 14 – 16, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO Richard Scarrott, CFO

VIEW EVENT

Advances in Achondroplasia Conference 2023

Frankfurt/Main

April 21 – 22, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO

VIEW EVENT

2nd Annual mRNA-Based Therapeutics Summit

Europe Berlin

January 24 – 26, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO

VIEW EVENT

JPM 2023 41st Annual Healthcare Meeting

San Francisco

January 9 – 12, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO Richard Scarrott, CFO

VIEW EVENT

BIO-Europe

Berlin

October 24 – 26, 2022

Attending:
Dr Michael Welsh, CSO Dr Spiros Servos, BD

VIEW EVENT

RNA Leaders USA Congress

Boston

October 18 – 19, 2022

Attending:
Dr Suzanne Saffie-Siebert, CEO Richard Scarrott, CFO

VIEW EVENT

ARM Cell & Gene Meeting on the Mesa

October 11 – 13, 2022

Attending:
Dr Spiros Servos, BD

VIEW EVENT

Next